RAVAX (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023




$ 3495

In Stock

RAVAX (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023


Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.

IRBP is producing RAVAX, a Phase III, potential first-in-class vaccine for the treatment of patients with early RA or with RA for less than 10 years. RAVAX is a vaccine that contains four 17-20mer (amino acids) (IR501) or 40mer (IR703) peptides against the T-cell receptor, specifically targetting autoreactive T cells, thus reducing their activity. The RAVAX vaccine is believed to target autoreactive T cells, while not affecting normal cells (IRBP, 2014b).


- Overview of Rheumatoid Arthritis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on RAVAX including product description, safety and efficacy profiles as well as a SWOT analysis

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of RAVAX performance.